Mats Eriksson

Publications
CV
Public outreach and news

Articles

Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2024;31(15):1792-1803
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study
Ray KK; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrieres J; Laufs U; Mostaza JM; Nanchen D; Bardet A; Lamparter M; Chhabra R; Soronen J; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
Article: CARDIOVASCULAR DIABETOLOGY. 2023;22(1):261
Prevalence of atherosclerosis in individuals with prediabetes and diabetes compared to normoglycaemic individuals-a Swedish population-based study
Ostgren CJ; Otten J; Festin K; Angeras O; Bergstrom G; Cederlund K; Engstrom G; Eriksson MJ; Eriksson M; Fall T; Gummesson A; Hagstrom E; Hellman U; James SK; Jernberg T; Kihlberg J; Kylhammar D; Markstad H; Nilsson P; Persson A; Persson M; Pirazzi C; Renklint R; Rosengren A; Soderberg S; Sundstrom J
Article: LANCET REGIONAL HEALTH-EUROPE. 2023;29:100624
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study
Ray KK; Haq I; Bilitou A; Manu MC; Burden A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrieres J; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(2):296-307
Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice
Pramfalk C; Ahmed O; Pedrelli M; Minniti ME; Luquet S; Denis RG; Olin M; Hardfeldt J; Vedin L-L; Steffensen KR; Ryden M; Hodson L; Eriksson M; Parini P
Article: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. 2022;28(18):2038-2047
Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up
Littmann K; Hagstrom E; Habel H; Bottai M; Eriksson M; Parini P; Brinck J
Article: ATHEROSCLEROSIS PLUS. 2021;43:24-30
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe-Methodology and rationale for the multinational observational SANTORINI study
Ray KK; Haq I; Bilitou A; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrieres J; Hildebrandt P; Laufs U; Mostaza JM; Nanchen D; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
Article: JOURNAL OF INTERNAL MEDICINE. 2021;290(2):404-415
Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia
Benedek P; Jiao H; Duvefelt K; Skoog T; Linde M; Kiviluoma P; Kere J; Eriksson M; Angelin B
Article: DIABETES CARE. 2020;43(8):1851-1858
The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes
Littmann K; Wodaje T; Alvarsson M; Bottai M; Eriksson M; Parini P; Brinck J
Article: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS. 2020;1865(6):158659
Generation of new hepatocyte-like in vitro models better resembling human lipid metabolism
Pramfalk C; Jakobsson T; Verzijl CRC; Minniti ME; Obensa C; Ripamonti F; Olin M; Pedrelli M; Eriksson M; Parini P
Article: EUROPEAN HEART JOURNAL: CASE REPORTS. 2020;4(1):1-6
Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report
Littmann K; Szummer K; Hagstrom H; Dolapcsiev K; Brinck J; Eriksson M
Article: MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2020;499:110604
Diiodothyronines regulate metabolic homeostasis in primary human hepatocytes by modulating mTORC1 and mTORC2 activity
Gnocchi D; Ellis ECS; Johansson H; Eriksson M; Bruscalupi G; Steffensen KR; Parini P
Article: EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES. 2019;5(3):225-232
Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data
Lindh M; Banefelt J; Fox KM; Hallberg S; Tai M-H; Eriksson M; Villa G; Svensson MK; Qian Y
Article: DIGESTIVE AND LIVER DISEASE. 2019;51(7):1016-1022
Genetic depletion of Soat2 diminishes hepatic steatosis via genes regulating de novo lipogenesis and by GLUT2 protein in female mice
Ahmed O; Pramfalk C; Pedrelli M; Olin M; Steffensen KR; Eriksson M; Parini P
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2018;7(24):e009876
Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
Ahmed O; Littmann K; Gustafsson U; Pramfalk C; Oorni K; Larsson L; Minniti ME; Sahlin S; Camejo G; Parini P; Eriksson M
Article: JOURNAL OF INTERNAL MEDICINE. 2018;284(6):674-684
Genetic testing for familial hypercholesterolemia among survivors of acute coronary syndrome
Benedek P; Eriksson M; Duvefelt K; Freyschuss A; Frick M; Lundman P; Nylund L; Szummer K
Article: ATHEROSCLEROSIS. 2018;275:246-255
Overexpression of transforming growth factor β induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption
Parini P; Melhuish TA; Wotton D; Larsson L; Ahmed O; Eriksson M; Pramfalk C
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2017;377(9):839-848
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE; Ørsted DD; Brown-Frandsen K; Marso SP; Poulter NR; Rasmussen S; Tornøe K; Zinman B; Buse JB; LEADER Steering Committee and Investigators
Article: JOURNAL OF INTERNAL MEDICINE. 2017;281(6):575-585
Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III
Laskar MG; Eriksson M; Rudling M; Angelin B
Article: EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2017;47(1):38-43
High-density lipoprotein-associated sphingosine-1-phosphate activity in heterozygous familial hypercholesterolaemia
Frias MA; Thomas A; Brulhart-Meynet M-C; Kovamees O; Pernow J; Eriksson M; Angelin B; James RW; Brinck JW
Article: JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2016;30(8):1631-1639
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population
Satman I; Rea RR; Eriksson M; Mosenzon O; Pratley R; Baeres FM; Orsted DD; Mann JF
Show more

All other publications

Editorial: JOURNAL OF INTERNAL MEDICINE. 2025;297(4):350-351
The combination of statin and ezetimibe is safe, effective, and preferable
Eriksson M
Editorial: JOURNAL OF INTERNAL MEDICINE. 2019;286(6):723-725
How to handle hypertriglyceridaemia in acute pancreatitis - Still a vote for conservatives?
Eriksson M; Angelin B
Meeting abstract: ATHEROSCLEROSIS. 2019;287:E111
LIPOPROTEIN (A) PLASMA LEVELS AND ASSOCIATION TO CARDIOVASCULAR DISEASE IN A STOCKHOLM COUNTY COHORT - A RETROSPECTIVE OBSERVATIONAL COHORT REGISTRY STUDY
Littmann K; Brinck J; Eriksson M; Parini P
Review: LAKARTIDNINGEN. 2019;116:FLMW
[Sweden introduces a new specific ICD-10 code for the disease familial hypercholesterolemia].
Brinck J; Hagström E; Benedek P; Hedelin R; Muhr T; Svennberg L; Reinhardt W; Eriksson M
Other: LAKARTIDNINGEN. 2018;115:E9YY
Tidig diagnos och behandling med gallsyra avgörande vid cerebrotendinös xantomatos.
Eggertsen G; Puschmann A; Hall S; Wärme A-K; Kvorning O; Olin M; Eriksson M; Björkhem I
Meeting abstract: ATHEROSCLEROSIS. 2018;275:E234
SIMVASTATIN AND EZETIMIBE REDUCE PLASMA LIPOPROTEIN BINDING TO HUMAN ARTERIAL PROTEOGLYCANS IN GALLSTONE DISEASED PATIENTS
Littmann K; Ahmed O; Gustafsson U; Pramfalk C; Oorni K; Larsson L; Sahlin S; Camejo G; Parini P; Eriksson M
Meeting abstract: ATHEROSCLEROSIS. 2018;275:E33
WHY ARE HUMANS LDL-ANIMALS AND MICE ARE NOT? HEPATIC APOB MRNA EDITING AND PLASMA PLTP ACTIVITY ARE THE CAUSE, NOT CETP
Minniti ME; Pedrelli M; Vedin L-L; Delbes A-S; Oorni K; Wilson EM; Luquet S; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS. 2018;275:E25
GENETIC DEPLETION OF THE SOAT2 GENE DIMINISHES DIET-INDUCED HEPATIC STEATOSIS AND IMPROVES GLUCOSE TOLERANCE IN MICE
Pramfalk C; Ahmed O; Larsson L; Hardfeldt J; Pedrelli M; Vedin L; Steffensen K; Tellez M; Delbes A; Denis R; Luquet S; Eriksson M; Parini P
Letter: JOURNAL OF INTERNAL MEDICINE. 2018;283(6):604-606
Unique case of cerebrotendinous xanthomatosis revisited: All the mutations responsible for this disease are present in the CYP27A1 gene
Jiao H; Olin M; Hansson M; Eggertsen G; Eriksson M; Angelin B; Bjorkhem I
Meeting abstract: ATHEROSCLEROSIS. 2017;263:E62
THE USE OF GENOTYPING AS A FIRST STEP IN MOLECULAR DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA
Benedek P; Angelin B; Duvefelt K; Hong J; Kere J; Rudling M; Eriksson M
Meeting abstract: ATHEROSCLEROSIS. 2016;252:E62
REMNANT CHOLESTEROL REDUCTION BY EZETIMIBE AND SIMVASTATIN DOES NOT AFFECT BILIARY LIPID CONCENTRATION IN GALLSTONE PATIENTS
Eriksson M; Ahmed O; Gustafsson U; Littman K; Sahlin S; Pramfalk C; Parini P
Meeting abstract: ATHEROSCLEROSIS. 2016;252:E240
WORKSHOP 2.2: ADIPOSE TISSUE - LIVER AXIS. SOAT2 DEPLETION IMPROVES INSULIN SENSITIVITY AND HEPATIC STEATOSIS
Parini P; Pramfalk C; Ahmed O; Larsson L; Karpe F; Neville M; Eriksson M
Published conference paper: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2015;1851(1):9-12
Role of TG-interacting factor (Tgif) in lipid metabolism
Pramfalk C; Eriksson M; Parini P
Review: EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY. 2012;114(6):624-633
Cholesteryl esters and ACAT
Pramfalk C; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2011;12(1):39
THE INHIBITION OF HEPATIC ACYL COENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) 2 POSITIVELY AFFECTS HDL METABOLISM AND FUNCTIONALITY IN MICE
Pedrelli M; Davoodpour P; Degirolamo C; Gomaraschi M; Larsson L; Rudel LL; Calabresi L; Gustafsson JA; Steffensen K; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2011;12(1):34
TG INTERACTING FACTOR ACTS AS A TRANSCRIPTIONAL REPRESSOR OF ACAT2 IN HUMAN
Pramfalk C; Eriksson M; Parini P
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2011;12(1):7
LIPID-LOWERING EFFECTS OF THE THYROID HORMONE ANALOGUE EPROTIROME REQUIRES FUNCTIONAL LDL RECEPTORS: STUDIES IN A HOMOZYGOUS FH PATIENT
Benedek P; Angelin B; Kristensen J; Rudling M; Eriksson M
Review: CURRENT OPINION IN LIPIDOLOGY. 2010;21(6):492-498
Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe
Thompson GR; Catapano A; Saheb S; Atassi-Dumont M; Barbir M; Eriksson M; Paulweber B; Sijbrands E; Stalenhoef AF; Parhofer KG
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2010;11(2):64
EFFECTS OF HIGH DOSE STATIN ON THE HUMAN HEPATIC EXPRESSION OF GENES INVOLVED IN CARBOHYDRATE AND TRIGLYCERIDE METABOLISM
Pramfalk C; Parini P; Gustafsson U; Sahlin S; Eriksson M
Published conference paper: CLINICAL THERAPEUTICS. 2010;32(4):615-625
Colesevelam Added to Combination Therapy With a Statin and Ezetimibe in Patients With Familial Hypercholesterolemia: A 12-Week, Multicenter, Randomized, Double-Blind, Controlled Trial
Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AFH; Imholz BPM; Durrington PN; Trip MD; Eriksson M; Visseren FLJ; Schaefer JR; Kastelein JJP
Show more

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2026-2028
Adjunct Professor, Department of Medicine, Huddinge, Karolinska Institutet, 2012-2023

Degrees and Education

Docent, 1993

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI